云南省猪戊型肝炎病毒全基因组扩增及进化分析

目的 对猪戊型肝炎病毒全长基因组进行扩增,分析其进化关系,为HEV的感染性克隆研究奠定基础。方法 利用巢式逆转录聚合酶链反应(RT-nPCR)和RACE技术对猪粪便中HEV样品进行全基因组扩增,利用DNAStar和MEGA4.0软件进行同源性比较和进化树分析。结果 RT-nPCR方法扩增出HEV的 5段目的基因序列和RACE技术扩增出HEV的 5'和3'端,序列比对结果正确,HEV全长扩增成功。同源性分析显示其与新疆株(GU119961)同源性较高(96.1%)。系统进化树显示该病毒属于基因4型h亚型猪HEV。结论 HEV全基因组序列扩增成功,为深入研究HEV奠定基础。     

Is asthma a protective factor for dengue fever? In vitro experiment and nationwide population-based cohort analysis

BackgroundDengue fever (DF) is the most rapidly spreading mosquito-borne viral disease. Practical vaccines or specific therapeutics are still expected. Environmental factors and genetic factors affect the susceptibility of Dengue virus (DV) infection. Asthma is a common allergic disease, with house dust mites (HDMs) being the most important allergens. Asthmatic patients are susceptible to several microorganism infections.MethodsA nationwide population-based cohort analysis was designed to assess whether to determine whether asthma can be a risk factor for DF.ResultsUnexpectedly, our data from a nationwide population-based cohort revealed asthmatic patients are at a decreased risk of DF. Compared to patients without asthma, the hazard ratio (HR) for DF in patients with asthma was 0.166 (95% CI: 0.118–0.233) after adjustment for possible confounding factors. In the age stratification, the adjusted HR for DF in young adult patients with asthma was 0.063. Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) of dendritic cells (DCs) is an important entry for DV. Through another in vitro experiment, we found that HDM can diminish surface expression of DC-SIGN in monocyte-derived DCs and further decrease the cellular entry of DV.ConclusionsDecreased DC-SIGN expression in DCs of allergic asthmatic patient may be one of many factors for them to be protected against DF. This could implicate the potential for DC-SIGN modulation as a candidate target for designing therapeutic strategies for DF.     

孕晚期注射HBIG阻断HBV母婴传播的病例对照研究

目的探讨孕晚期注射乙肝免疫球蛋白（HBIG）对阻断HBV母婴传播有无作用。方法选取538例孕晚期注射HBIG和817例未注射HBIG的孕妇及其婴儿,比较两组的宫内感染率。结果（1）HBIG组和对照组的宫内感染率分别为2．2％和1．1％,两组相比差异无统计学意义（P〉0．05）;（2）当母亲同为HBeAg阳性时,两组的宫内感染率相比,差异无统计学意义（4．14％VS．4．92％,P〉0．05）;当母亲同为HBVDNA阳性时,两组的宫内感染率相比,差异仍无统计学意义（3．14％vs．3．10％,P〉0．05）;（3）进一步将孕妇血清HBVDNA按浓度高低进行分层分析,当HBVDNA浓度相同时,两组的宫内感染率相比,差异无统计学意义（P〉0．05）。结论孕期注射HBIG对阻断HBV母婴传播无明显作用,不推荐孕期使用HBIG。